Genetic Basis and Outcome in a Nationwide Study of Finnish Patients with Hypertrophic Cardiomyopathy

Pertti Jääskeläinen(University of Eastern Finland), Johanna Kuusisto(University of Eastern Finland), Katriina Aalto‐Setälä(Tampere University), Sari Vanninen(Tampere University Hospital), Erkki Ilveskoski(Tampere University Hospital), Joose Raivo(University of Eastern Finland), Markku S. Nieminen(Cornell University), Teemu Kuulasmaa(University of Eastern Finland), Jagadish Vangipurapu(University of Eastern Finland), Markku Laakso(Cleveland Clinic), Liisa Hämäläinen(Vaasa Central Hospital), John Melin(Central Finland Health Care District), Tiina Heliö(Helsinki University Hospital), Maija Kaartinen(Savonlinna Central Hospital), Jorma Kokkonen(Walsh University)
ESC Heart Failure
February 18, 2019
10.1002/ehf2.12420
Cited by 46

Related Papers

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|5.4k
FinnGen provides genetic insights from a well-phenotyped isolated population
|Nature|2023|4.2k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
|The Lancet|2003|3.8k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k